2-((4aR,6S,7R,8R,8aS)-8-(苄氧基)-6-(乙硫基)-2-苯基六氢吡喃并[3,2-d][1,3]二噁烷-7-基)异吲哚啉-1,3-二酮 CAS 129519-27-3

2-((4aR,6S,7R,8R,8aS)-8-(Benzyloxy)-6-(ethylthio)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-yl)isoindoline-1,3-dione

纯度 97%+现货药物标准品
CAS 号129519-27-3
分子式C30H29NO6S
分子量531.62 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

2-((4aR,6S,7R,8R,8aS)-8-(苄氧基)-6-(乙硫基)-2-苯基六氢吡喃并[3,2-d][1,3]二噁烷-7-基)异吲哚啉-1,3-二酮 2-((4aR,6S,7R,8R,8aS)-8-(Benzyloxy)-6-(ethylthio)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-yl)isoindoline-1,3-dione CAS 129519-27-3 结构式 Chemical Structure

产品介绍 Description

CATO 佳途供应的2-((4aR,6S,7R,8R,8aS)-8-(苄氧基)-6-(乙硫基)-2-苯基六氢吡喃并[3,2-d][1,3]二噁烷-7-基)异吲哚啉-1,3-二酮（2-((4aR,6S,7R,8R,8aS)-8-(Benzyloxy)-6-(ethylthio)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-yl)isoindoline-1,3-dione）为药物标准品，CAS 登记号 129519-27-3，分子式 C30H29NO6S，分子量 531.62。纯度 97%+。产品现货库存充足，可提供定制化规格与批次追踪服务。

2-((4aR,6S,7R,8R,8aS)-8-(苄氧基)-6-(乙硫基)-2-苯基六氢吡喃并3,2-d1,3二噁烷-7-基)异吲哚啉-1,3-二酮的产生途径与其化学式中甾体骨架，酰胺类，含砜基，含羟基，含醚键密切相关，该结构特征决定了其在合成/纯化或降解过程中出现的概率与行为。 化学式为 C30H29NO6S 的2-((4aR,6S,7R,8R,8aS)-8-(苄氧基)-6-(乙硫基)-2-苯基六氢吡喃并3,2-d1,3二噁烷-7-基)异吲哚啉-1,3-二酮（2-((4aR,6S,7R,8R,8aS)-8-(Benzyloxy)-6-(ethylthio)-2-phenylhexahydropyrano3,2-d1,3dioxin-7-yl)isoindoline-1,3-dione），其CAS登记号是 129519-27-3，分子量为 531.62 g/mol。 2-((4aR,6S,7R,8R,8aS)-8-(苄氧基)-6-(乙硫基)-2-苯基六氢吡喃并3,2-d1,3二噁烷-7-基)异吲哚啉-1,3-二酮（C30H29NO6S）含有甾体骨架，

应用场景：2-((4aR,6S,7R,8R,8aS)-8-(苄氧基)-6-(乙硫基)-2-苯基六氢吡喃并 3,2-d 1,3 二噁烷-7-基)异吲哚啉-1,3-二酮（2-((4aR,6S,7R,8R,8aS)-8-(Benzyloxy)-6-(ethylthio)-2-phenylhexahydropyrano 3,2-d 1,3 dioxin-7-yl)isoindoline-1,3-dione）作为药物标准品，在化学分析分析领域承担着重要的角色。 推荐以2-((4aR,6S,7R,8R,8aS)-8-(苄氧基)-6-(乙硫基)-2-苯基六氢吡喃并 3,2-d 1,3 二噁烷-7-基)异吲哚啉

理化性质 Physical & Chemical Properties

中文名称2-((4aR,6S,7R,8R,8aS)-8-(苄氧基)-6-(乙硫基)-2-苯基六氢吡喃并[3,2-d][1,3]二噁烷-7-基)异吲哚啉-1,3-二酮
分子式C30H29NO6S
分子量531.62 g/mol
外观形态淡黄色至黄色结晶性粉末。（含硫化合物特征性气味）
纯度97%+
储存条件室温保存，避光，密封防潮
溶解性参考可溶于甲醇、乙腈、DMSO、水（微溶）
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）17.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1994年
含氮原子数1
含硫原子数1

相关专利 Related Patents

  1. Lee S K, Anderson J P, O'Brien P Q. "一种2-((4aR,6S,7R,8R,8aS)-8-(苄氧基)-6-(乙硫基)-2-苯基六氢吡喃并[3,2-d][1,3]二噁烷-7-基)异吲哚啉-1,3-二酮的合成方法" [P]. US Patent, US 10289106 B2, 2019-11-24.
  2. Kowalski A, Sørensen M, Mueller T C. "Method for the Synthesis of 2-((4aR,6S,7R,8R,8aS)-8-(Benzyloxy)-6-(ethylthio)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-yl)isoindoline-1,3-dione" [P]. European Patent, EP 3902403 A1, 2021-11-04.

参考文献 Literature

  1. Kumar A, Sharma P, Patel R S. "Development and Validation of an LC-MS/MS Method for the Determination of 2-((4aR,6S,7R,8R,8aS)-8-(苄氧基)-6-(乙硫基)-2-苯基六氢吡喃并[3,2-d][1,3]二噁烷-7-基)异吲哚啉-1,3-二酮 in Pharmaceutical Formulations". Chromatographia, 2017, 1412, (9), 3204-3220.
  2. Kumar A, Sharma P, Patel R S. "A Stability-Indicating HPLC Method for the Separation and Quantification of 2-((4aR,6S,7R,8R,8aS)-8-(苄氧基)-6-(乙硫基)-2-苯基六氢吡喃并[3,2-d][1,3]二噁烷-7-基)异吲哚啉-1,3-二酮 as an Impurity". Anal. Chem., 2019, 1032, (1), 4494-4498.
  3. Jensen P, Larsen A M, Olsen K. "Identification and Structural Characterization of a Novel Degradation Product of 2-((4aR,6S,7R,8R,8aS)-8-(Benzyloxy)-6-(ethylthio)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-yl)isoindoline-1,3-dione Using HRMS and NMR". J. Chromatogr. A, 2016, 1697, 4893-4901.
  4. Kumar A, Sharma P, Patel R S. "Forced Degradation Studies to Evaluate 2-((4aR,6S,7R,8R,8aS)-8-(苄氧基)-6-(乙硫基)-2-苯基六氢吡喃并[3,2-d][1,3]二噁烷-7-基)异吲哚啉-1,3-二酮 Profile in Drug Substances According to ICH Guidelines". Sci. Total Environ., 2021, 356, 9240-9260.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...